Have you implemented circulating tumor DNA (ctDNA) monitoring in your practice? Join us to learn about how ctDNA-based treatment response monitoring (TRM) can provide objective insights into a patient’s response – potentially earlier than traditional methods like imaging. Expert speakers will share information and perspectives about the role of TRM, as well as emerging data. Foundation Medicine speakers will share insights from our personalized tissue-informed ctDNA monitoring test now available in the United States, FoundationOne®Tracker. This 30-minute session includes discussion and Q&A.